.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,726,673

« Back to Dashboard

Details for Patent: 6,726,673

Title: Methods and apparatus for improved administration of testosterone pharmaceuticals
Abstract:The present invention relates to a method and apparatus for increasing the delivery rate of an androgen transdermal therapeutic system through the skin. An androgen transdermal therapeutic system can be applied to a patient's skin for delivery of the androgen. A temperature modification apparatus which is capable of generating controlled heat is applied approximate to the androgen transdermal therapeutic system. The heating from the temperature modification apparatus raises the temperature of the androgen transdermal therapeutic system and raises the temperature of the patient's skin to achieve an increased rate of delivery of androgen through the skin. The controlled heat can also be used to adjust dosage rates of the androgen transdermal therapeutic system and to mimic natural circadian patterns. The controlled heating may also be used to improve or regulate the release of androgen from injected/implanted extended/controlled release systems.
Inventor(s): Zhang; Jie (Salt Lake City, UT), Zhang; Hao (Midvale, UT), Hull; Wade A. (Taylorsville, UT), Rigby; Larry (Salt Lake City, UT)
Assignee: Zars, Inc. (Salt Lake City, UT)
Filing Date:May 24, 1999
Application Number:09/317,313
Claims:1. A method of increasing the delivery rate of an androgen transdermal therapeutic system through skin to correspond to a natural circadian pattern, the method comprising: applying an androgen transdermal therapeutic system to the skin for delivery of androgen; applying an apparatus capable of generating heat proximate the androgen transdermal therapeutic systems and configured to create heat in a manner that mimics the endogenous circadian androgen production; and heating the androgen transdermal therapeutic system with the apparatus capable of generating heat at a safe, pre-designed temperature for a safe, pre-designed length of time to achieve an increased rate of delivery of androgen through the skin to simulate to a natural circadian pattern.

2. The method of claim 1, wherein the step of applying the apparatus capable of generating heat proximate to the androgen transdermal therapeutic system comprises applying a temperature modification apparatus to the androgen transdermal therapeutic systems.

3. The method of claim 1, wherein the step of heating the androgen transdermal therapeutic system includes heating said skin to a temperature of between about 38 and 45.degree. C.

4. The method of claim 1, wherein the step of heating the androgen transdermal therapeutic system includes heating said skin to a temperature of between about 39 and 43.degree. C.

5. The method of claim 1, wherein the step of heating the androgen transdermal therapeutic system includes heating said skin up to a temperature of about 50.degree. C.

6. The method of claim 1, wherein the step of heating the androgen transdermal therapeutic system effectuates an increase in the rate of androgen delivery to the human body through increasing skin permeability.

7. The method of claim 1, wherein the step of heating the androgen transdermal therapeutic system effectuates an increase in the rate of androgen delivery through increasing the permeability of blood vessel walls in the skin and subskin tissues.

8. The method of claim 1, wherein the step of heating the androgen transdermal therapeutic system effectuates an increase in the rate of androgen delivery to the human body through increasing circulation of body fluid in the skin and subskin tissues proximate the androgen transdermal therapeutic systems.

9. The method of claim 1, further including the step of reducing heating of the skin under the androgen transdermal therapeutic system with the temperature modification apparatus after a desired concentration of target androgen in the human body is achieved after a predetermined period of time.

10. The method of claim 1, further including the step of removing the temperature modification apparatus when a desired concentration of target androgen in the human body is achieved.

11. The method of claim 1, wherein the delivery system androgen is testosterone.

12. The method of claim 1, wherein the delivery system androgen is a testosterone derivative.

13. The method of claim 1, wherein the temperature modification apparatus comprises a chamber containing a medium capable of generating heat when exposed to oxygen.

14. The method of claim 1, wherein the temperature modification apparatus comprises a chamber containing reactants capable of undergoing exothermic oxidation when exposed to oxygen.

15. The method of claim 13, wherein the medium capable of generating heat when exposed to oxygen comprises iron powder and activated carbon.

16. The method of claim 13, wherein the chamber is comprised of parts being substantially impermeable to oxygen and a structure which allows a predetermined flow rate of ambient oxygen into said medium capable of generating heat inside said chamber.

17. The method of claim 16, wherein said structure comprises a cover substantially impermeable to oxygen, said cover having holes, the holes being covered by a membrane with selected oxygen permeability.

18. The method of claim 1, wherein the increased rate of delivery of the delivery system androgen through the skin is sufficient to provide a desired increased concentration of the target androgen in the systemic circulation.

19. The method of claim 1, wherein the increased rate of delivery of androgen through the skin is used to facilitate the establishment of target androgen concentration vs. time relationship that mimics the natural human circadian pattern.

20. The method of claim 19, including the step of discontinuing the heating when the desired concentration of androgen in the systemic circulation in the body is achieved.

21. The method of claim 20, the step of heating the androgen transdermal therapeutic system continues for a predetermined time, the predetermined time of heating being a time sufficient to obtain desired increased concentration levels of androgen within a patient's systemic circulation.

22. The method of claim 20, wherein the predetermined time is between one and five hours following the initiation of the heating step.

23. A method of reducing the time it takes to achieve a desired, increased concentration of a target androgen in a systemic circulation of a human body comprising: applying an androgen transdermal therapeutic system to the skin of the human body for delivery of therapeutic androgen to the systemic circulation of the human body; applying a temperature control apparatus capable of generating heat proximate the androgen transdermal therapeutic system and configured to create heat in a manner that mimics the endogenous circadian androgen production; and heating the skin under the androgen transdermal therapeutic systems with the temperature control apparatus to reduce the time it takes to achieve a desired increased concentration of the target androgen in the systemic circulation of the human body.

24. The method of claim 23, wherein the step of applying the temperature control apparatus capable of generating heat proximate the androgen transdermal therapeutic system further comprises applying the temperature control apparatus directly to the androgen transdermal therapeutic systems.

25. The method of claim 23, wherein the step of heating the androgen transdermal therapeutic system includes heating the skin to a temperature of between about 38 and 45.degree. C.

26. The method of claim 23, wherein the step of heating the skin under the androgen transdermal therapeutic system includes heating the skin to a temperature of between about 39 and 43.degree. C.

27. The method of claim 23, wherein the step of heating the skin under the androgen transdermal therapeutic system includes heating the skin up to a temperature of about 50.degree. C.

28. The method of claim 23, wherein the step of heating the skin under the androgen transdermal therapeutic system effectuates reducing the time it takes to achieve a desired, increase concentration of the target androgen in said systemic circulation of said human body through increasing skin permeability by heating.

29. The method of claim 23, wherein the step of heating the skin under said androgen transdermal therapeutic system effectuates reducing the time it takes to achieve a desired, increase concentration of the target androgen in the systemic circulation of the human body through increasing the permeability of blood vessel walls in sub-skin tissues by the heating.

30. The method of claim 23, wherein the step of heating the skin under the androgen transdermal therapeutic system effectuates reducing the time it takes to achieve a desired, increase concentration of the target androgen in the systemic circulation of the human body through increasing circulation of body fluid proximate the transdermal androgen deliver system by heating.

31. The method of claim 23, further comprising the step of reducing said heating of the skin under the androgen transdermal therapeutic system with the temperature control apparatus after a desired increase in concentration of target androgen in the systemic circulation in the human body is achieved.

32. The method of claim 23, wherein the desired increase in concentration of the target androgen in the systemic circulation in the human body is a concentration which facilitates the mimicking of natural human circadian patterns.

33. The method of claim 23, wherein the desired increase in concentration of the target androgen is achieved between the range of about one to about five hours after the step of applying the temperature control apparatus.

34. The method of claim 33, wherein the desired increased concentration of the target androgen in the systemic circulation in the human body is a concentration which facilitates the mimicking of natural human circadian patterns.

35. The method of claim 34, wherein the concentration peaks in the morning.

36. The method of claim 35, wherein the target androgen is testosterone.

37. The method of claim 23, wherein the temperature control apparatus comprises a chamber containing a medium capable of generating heat when exposed to oxygen.

38. The method of claim 23, wherein the temperature control apparatus comprises a chamber containing reactants capable of undergoing exothermic oxidation when exposed to oxygen.

39. The method of claim 37, wherein the medium capable of generating heat when exposed to oxygen comprises an iron powder and activated carbon formulation.

40. The method of claim 37, wherein the chamber is comprised of parts being substantially impermeable to oxygen and a structure which allows a predetermined flow rate of ambient oxygen into the medium capable of generating heat inside the chamber.

41. The method of claim 40, wherein said structure comprises a cover substantially impermeable to oxygen, the cover defining holes, the holes being covered by a membrane with selected oxygen permeability.

42. The method of claim 23, wherein the increased rate of delivery of androgen through the skin is sufficient to provide a desired increased concentration of the target androgen in the systemic circulation, the desired concentration being a concentration which facilitates the mimicking of natural human circadian patterns.

43. The method of claim 42, including the step of discontinuing the heating when the desired increased concentration of the target androgen in the systemic circulation in the body is achieved.

44. The method of claim 43, wherein the step of heating the skin under the androgen transdermal therapeutic system continues for a predetermined time.

45. The method of claim 44, wherein the predetermined time of heating is a time sufficient to obtain a desired increased concentration of the target androgen within a patient's systemic circulation.

46. The method of claim 45, wherein the predetermined time is between the range of about one and five hours following the initiation of the heating step.

47. A method for adjusting a rate of androgen delivery from an androgen transdermal therapeutic system through the skin to mimic a natural circadian pattern, the method comprising: placing an androgen transdermal therapeutic system on the skin applying a temperature control apparatus configured to create heat in a manner that mimics the endogenous circadian androgen production; heating the skin under said androgen transdermal therapeutic system to a safe, predetermined temperature range for a safe, predesigned length of time; and terminating said heating after the predesigned length of time to mimic the natural circadian pattern.

48. The method as claimed in claim 47, wherein the androgen is testosterone.

49. The method as claimed in claim 47 wherein the androgen is a derivative of testosterone.

50. The method of claim 47 further comprising the step of reducing said heating.

51. The method of claim 50 further comprising the steps of repeating the steps of heating the skin and reducing said heating.

52. A method for obtaining varying serum androgen release rates into the systemic circulation of the human body that correspond to a natural circadian pattern from otherwise substantially constant release delivery systems injected or implanted in said human body, the method comprising: administering a controlled/extended release androgen therapeutic system in a target site within 3 cm from the skin surface, applying a control heating apparatus on the skin proximate to the target site configured to create heat in a manner that mimics the endogenous circadian androgen production; and heating the androgen therapeutic system to a safe, predesigned temperature for a safe, predesigned length of time to correspond to the natural circadian pattern.

53. The method as claimed in claim 52, wherein the step of administering controlled release androgen therapeutic system comprises injecting an extended release androgen formulation.

54. The method as claimed in claim 53, wherein the step of applying a controlled heating apparatus on the skin proximate to the target site comprises placing a CHADD patch on the skin above the implanted formulation in the morning to mimic the natural circadian pattern of testosterone concentrations in the systemic circulation of a human body.

55. The method of claim 54 wherein the CHADD patch comprises a chamber defined by a bottom wall, a top wall and side walls, the bottom wall, top wall and side walls of the chamber being made of flexible substantially air impermeable material, the air impermeable material defining at least one hole through material, and a temperature regulating mechanism disposed within the chamber, the temperature regulating mechanism comprising reactants capable of creating an exothermic oxidation reaction when exposed to oxygen.

56. The apparatus as in claim 55, wherein the temperature regulating mechanism comprises a mixture of activated carbon, iron powder, and water.

57. A method of mimicking a variation of testosterone concentrations in the blood of the human body according to a natural circadian pattern, the method comprising the steps of: administrating an integrated patch capable of delivering androgen and capable of delivering controlled heat in a manner that mimics the endogenous circadian androgen production to the skin of a patient; elevating the patient's skin temperature proximate to the integrated patch to a safe, predesigned temperature for a safe, predesigned length of time using controlled heat, thereby allowing increased absorption of androgen that human body according to the natural circadian pattern; and maintaining said increased absorption by said controlled heat for the predesigned length of time.

58. The method of claim 55, where in the desired period of time is in the range of about 1-10 hours and the step of administering the patch is done in the morning to properly mimic the patient's natural circadian pattern.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc